[Skip to Navigation]
January 15, 2020

At Last, One Indication for Left Ventricular Assist Devices—A Bridge to a Better and Longer Life

Author Affiliations
  • 1Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
  • 2Now with Division of Cardiology, Department of Medicine, Long School of Medicine, University of Texas, San Antonio
JAMA Cardiol. 2020;5(3):251-252. doi:10.1001/jamacardio.2019.5592

In this issue of JAMA Cardiology, Goldstein et al1 report on a prespecified analysis of the previously published Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM III) trial.2 Their results suggest that older, well-known indications for left ventricular assist device (LVAD) implant in patients with advanced heart failure, bridge to transplant (BTT) and destination therapy (DT), are no longer clinically distinctive in the current era of durable mechanical circulatory support (MCS).

Add or change institution